Otezla Is Amgen’s Main Growth Driver As Net Drug Pricing Declines
Executive Summary
Without the newly purchased drug, Amgen’s 2020 sales would be flat, but the company hopes to enhance its psoriasis market push with its combined offering of Otezla, Enbrel and biosimilars.
You may also be interested in...
J.P. Morgan Day 1: Companies Make Deal-Making, COVID-19 Promises
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Business development is key topic for Amgen and Vertex; BioNTech talks COVID-19 vaccine supply while Merck KGAA's new CEO pledges to rise to meet the challenges posed by COVID-19.
J.P. Morgan Day 1: Companies Make Deal-Making, COVID-19 Promises
Daily round-up from the virtual J.P. Morgan Healthcare Conference: Business development is key topic for Amgen and Vertex; BioNTech talks COVID-19 vaccine supply while Merck KGAA's new CEO pledges to rise to meet the challenges posed by COVID-19.
Bristol’s Oral TYK2 Inhibitor Beats Amgen’s Otezla In Phase III
Bristol Myers Squibb released no detailed data from the first Phase III trial of deucravacitinib (BMS-986165) in psoriasis but said it achieved superiority to placebo and Otezla with safety similar to Phase II.
Need a specific report? 1000+ reports available
Buy Reports